2Saad F,Gleason DM,Murray R,et al.A randominsed,placebo-controlled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma:Zoledronic Acid Prostate Cancer Study Group.J Natl Cancer Inst,2002;94(19):1458-1468
3[3]Rosen LS, Gordon D, Antonio BS, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: Aphase Ⅲ double-blind, comparative trial. Cancer J, 2001, 7(5) :377
4[4]Green JR, Muller K, Jacquet AF, et al. Preclinical pharmacology of CGP429446, a new, potent, heterocyclic biphosphonate compound. J Bone Res, 1994, 9:745
5[5]Coukell A J, Markham A. Pamidronate: A review of its use in the maagement of osteolytic bone metastases, tumor-induced hypercalcaemia and Paget, s disease of bone. Drugs Aging,1998, 12:149
6[6]Rogers M J, Frith JC, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res, 1999, 14 (Suppl 2):53
7[7]Derenne S, Amiot M, Barille S. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res, 1999, 14 (12):2048
8[8]Clezardin P. The antitumor potential of bisphosphonates. Semin Oncol, 2002, 29 (Suppl 21):33
9[9]Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res, 1997,57 (18) :3890
10[10]Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res,2002, 62 (22):6538
7Real C, Turkiewicz A M, Reale C A. Antalgic treatment of pain associated with bone metastases [ J]. Crit Rev Oncol Hematol, 2001,37(1):1 - 11.
8Wellington K, Goa K L. Zoledronic acid : a review of its use in the management of bone metastases and hypercalcaemia of malignancy [J]. Drugs, 2003,63(4) :417.
